New antiretroviral drugs

Current antiretroviral drugs for human immunodeficiency virus infection: review article

Currently, there are about 37 million people worldwide living with human immunodeficiency virus (HIV) /AIDS, with an estimated two million new cases per year globally. According to estimates from the World Health Organization (WHO), only 75% of the population with HIV know their status. Initially, HIV infection was associated with significantly increased rates of mortality and morbidity. Howeve...

Antiretroviral therapy: new drugs, formulations, ideas, and strategies.

There is a continuing need for new antiretroviral drugs and formulations and updated strategies for using new and established drugs. Strategies being investigated for expanding initial treatment options include use of rilpivirine, raltegravir, or maraviroc as an alternative to efavirenz, use of pharmacokinetics enhancers without anti-HIV activity as an alternative to ritonavir as a boosting age...

[Pharmacogenetics of antiretroviral drugs].

Interactions between recreational drugs and antiretroviral agents.

OBJECTIVE To summarize existing data regarding potential interactions between recreational drugs and drugs commonly used in the management of HIV-positive patients. DATA SOURCES Information was obtained via a MEDLINE search (1966-August 2002) using the MeSH headings human immunodeficiency virus, drug interactions, cytochrome P450, medication names commonly prescribed for the management of HIV...

Antiretroviral drugs, genotoxicity, and adverse effects

ents and also specifically for reducing the risk of mother-to-child transmission of HIV in relation to pregnancy and childbirth. In this report we review the consequences that have been demonstrated for children following in utero exposure of these drugs. We focus mainly on the groups of drugs that are known to be potentially genotoxic (NRTIs). The risk of cancer-development is the concern that...